SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-012447
Filing Date
2021-01-20
Accepted
2021-01-20 16:23:01
Documents
15
Period of Report
2021-01-19
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d161128d8k.htm   iXBRL 8-K 43787
2 EX-99.1 d161128dex991.htm EX-99.1 17810
6 GRAPHIC g113734g0117075656595.jpg GRAPHIC 3421
7 GRAPHIC g113734g0117075656844.jpg GRAPHIC 2865
  Complete submission text file 0001193125-21-012447.txt   208230

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eidx-20210119.xsd EX-101.SCH 3054
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eidx-20210119_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eidx-20210119_pre.xml EX-101.PRE 11849
8 EXTRACTED XBRL INSTANCE DOCUMENT d161128d8k_htm.xml XML 3455
Mailing Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 650-391-9740
Eidos Therapeutics, Inc. (Filer) CIK: 0001731831 (see all company filings)

IRS No.: 463733671 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38533 | Film No.: 21539016
SIC: 2834 Pharmaceutical Preparations